Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

February 28, 2019

Study Completion Date

January 31, 2020

Conditions
Influenza A Subtype H5N1 Infection
Interventions
BIOLOGICAL

Seasonal Influenza Vaccine

A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study

BIOLOGICAL

Seasonal Influenza Vaccine

A single dose of the FDA-approved 2018-2019 seasonal influenza vaccine (Fluarix Quadrivalent) will be administered to the subjects participated in HIPCVAX-010 Study

Trial Locations (1)

30030

The Hope Clinic of Emory University, Decatur

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Emory University

OTHER